Search by Drug Name or NDC
NDC 00002-1457-80 MOUNJARO 15 mg/.5mL Details
MOUNJARO 15 mg/.5mL
MOUNJARO is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eli Lilly and Company. The primary component is TIRZEPATIDE.
MedlinePlus Drug Summary
Tirzepatide is used along with diet and exercise to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Tirzepatide is in a class of medications called glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonists. It works by increasing insulin available and decreasing glucagon (a hormone that controls the amount of glucose made by the liver) available in the body.
Related Packages: 00002-1457-80Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Tirzepatide injection
Product Information
| NDC | 00002-1457 |
|---|---|
| Product ID | 0002-1457_b597917f-9673-4331-809d-79a538bb943c |
| Associated GPIs | 2717308000D235 |
| GCN Sequence Number | 083390 |
| GCN Sequence Number Description | tirzepatide PEN INJCTR 15MG/0.5ML SUBCUT |
| HIC3 | C4Z |
| HIC3 Description | ANTIHYPERGLYCEMIC - INCRETIN MIMETICS COMBINATION |
| GCN | 52335 |
| HICL Sequence Number | 048014 |
| HICL Sequence Number Description | TIRZEPATIDE |
| Brand/Generic | Brand |
| Proprietary Name | MOUNJARO |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | tirzepatide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 15 |
| Active Ingredient Units | mg/.5mL |
| Substance Name | TIRZEPATIDE |
| Labeler Name | Eli Lilly and Company |
| Pharmaceutical Class | G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA215866 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00002-1457-80 (00002145780)
| NDC Package Code | 0002-1457-80 |
|---|---|
| Billing NDC | 00002145780 |
| Package | 4 SYRINGE in 1 CARTON (0002-1457-80) / .5 mL in 1 SYRINGE (0002-1457-01) |
| Marketing Start Date | 2022-05-13 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 514.886 |
| Pricing Unit | ML |
| Effective Date | 2024-01-01 |
| NDC Description | MOUNJARO 15 MG/0.5 ML PEN |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis